
SRRK Stock Forecast & Price Target
SRRK Analyst Ratings
Bulls say
Scholar Rock Holding is in a good position for growth with their pipeline candidates, including apitegromab and SRK-439. The recent regulatory interactions and updates, along with the company's preparations for launch upon approval, indicate that the manufacturing setbacks have been resolved and the focus can shift back to the drug's efficacy and potential in treating SMA. Additionally, clearance from the FDA for the BLA resubmission and a CHMP meeting for apitegromab's MAA in Europe reinforce the company's potential for success. However, there are some risks to consider, such as competition and the possibility of the drugs not showing sufficient efficacy. Overall, the positive outlook for Scholar Rock Holding is supported by strong clinical data and potential for growth in the rare neuromuscular disease market.
Bears say
Scholar Rock Holding is currently experiencing significant delays in the launch of their potential SMA treatment, apitegromab, due to regulatory issues with their manufacturing facility. This delay introduces uncertainty and variability into the timeline and could potentially hurt the company's growth prospects and long-term valuation. Additionally, the company's success relies heavily on the expansion of their pipeline beyond SMA, and any further issues with Apitegromab's launch could hinder these efforts.
This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.
SRRK Analyst Forecast & Price Prediction
Start investing in SRRK
Order type
Buy in
Order amount
Est. shares
0 shares